Electromed, Inc. Earnings Recaps
Q4 2026
Aug 28, 2026
Electromed’s shares dropped 21.1% following a notable hospital revenue decline of 29% and cautious commentary around the slower, unpredictable hospital channel. Despite growth in home care and distributor channels, the market reacted negatively to the deceleration and the still uncertain hospital sales outlook.
Key takeaways
- Total net revenue reached a record $19.4 million, up 12% year-over-year, driven by a 15% increase in the core home care channel and modest 2% growth in distribution.
- Hospital revenue fell 29%, reflecting longer sales cycles and inherent unpredictability, which pressured overall growth expectations.
- Operating income grew 26% year-over-year to $3.8 million, with earnings per share reaching $0.39.
- Sales force expanded by 6 reps, preparing for planned territory expansion in fiscal 2027.
- Payer coverage expanded to 87% of U.S. covered lives, including 40 new contracts adding over 6 million covered lives, supporting long-term market access.
Q3 2026
May 13, 2026
Electromed’s Q3 results surpassed expectations, driving a 31.2% stock rally, powered by broad-based revenue growth, significant margin expansion, and strong execution in both commercial and clinical initiatives.
Key takeaways
- Revenue grew 18.4% year-over-year to $18.6 million, supported by a 19% increase in Home Care and a 43% rebound in Hospital sales.
- Operating income surged 76% to $3.8 million, reflecting meaningful margin improvement.
- Diluted EPS rose 67% to $0.35, marking continued profitability gains.
- The company advanced adoption with over 40% of orders through its Smart Order ePrescribe system, shortening shipment times by 5 days.
- Clinical education efforts and the Triple Down on Bronchiectasis campaign are driving awareness in a large underpenetrated patient market.
Q2 2026
Feb 11, 2026
Electromed, Inc. delivered a standout performance in Q2 FY 2026 with record revenue of $18.9 million, marking the thirteenth consecutive quarter of revenue and profit growth, despite a strategic pullback in hospital shipments.
Key takeaways
- Revenue increased by 16.3% year-over-year, driven by an 18.4% rise in the Home Care segment.
- Operating income grew 42.4% year-over-year to $3 million, with an operating income margin of 19%.
- The "Triple Down on Bronchiectasis" campaign launched to target a significant unmet need in bronchiectasis care, addressing potential expansion to 800,000 underserved patients.
- 25 new payer contracts were secured, expanding coverage to an additional 2.9 million lives, enhancing market access for SmartVest.
- Implementation of digital solutions, including the Smart Order e-prescribe, streamlined order fulfillment, with over one-third of orders now processed through this platform.